Acridine carboxamide

Acridine carboxamide (N-[(2'-dimethylamino)ethyl]acridine-4-carboxamide) is an chemotherapy agent that is being studied in the treatment of cancer. It belongs to the family of drugs called topoisomerase inhibitors.

While the agent was well-tolerated in Phase II clinical trials, it did not show efficacy when tested against various types of cancers.^[1][2][3][4]

References

1. ^ Dittrich C, Dieras V, Kerbrat P et al. (2003). "Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer". Investigational new drugs 21 (3): 347–52. doi:10.1023/A:1025476813365. PMID 14578683. 
2. ^ Caponigro F, Dittrich C, Sorensen JB et al. (2002). "Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer". Eur. J. Cancer 38 (1): 70–4. doi:10.1016/S0959-8049(01)00336-7. PMID 11750842. 
3. ^ Twelves C, Campone M, Coudert B et al. (2002). "Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme". Ann. Oncol. 13 (5): 777–80. doi:10.1093/annonc/mdf121. PMID 12075748. 
4. ^ Dittrich C, Coudert B, Paz-Ares L et al. (2003). "Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer". Eur. J. Cancer 39 (3): 330–4. doi:10.1016/S0959-8049(02)00559-2. PMID 12565985.